Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)

Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC.However, the clinical benefit of this combination in older patients is controversial.We performed a meta-analysis of phase III randomized trials that compared PD-1/ PD-L1 inhibitor plus CT with CT alone in first line of treatment for older patients with advanced NSCLC.Subgroups of patients over 65 and over 75 were analyzed.The outcomes included overall survival (OS) and progression-free survival (PFS).A fixedeffect model was used.We analyzed ten trials with an anti-PD-1 (camrelizumab, cemiplimab, nivolumab, pembrolizumab, tislelizumab or toripalimab) and six trials with an anti-PD-L1 (atezolizumab, durvalumab or sugemalimab), including 3666 patients over the age of 65 (41%) and 282 patients over the age of 75 (<10%).For patients over 65 years of age, anti-PD-1/PD-L1 + CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.79 [0.72-0.86];p < 0.00001) and P FS (0.63 [0.58-0.68];p < 0.00001) compared to CT alone.Survival benefits occurred in both anti-PD-1 and anti-PD-L1 trials.For patients over 75 years of age, OS benefit was not statistically significant (0.88 [0.67-1.16];p = 0.37).For patients over the age of 65 with untreated NSCLC, the anti-PD-1/PD-L1 combination with CT, compared with CT alone, is associated with significantly improved OS and PFS.Due to the low number of patients, it is difficult to conclude for those over 75.